Patents by Inventor Andreas Reik

Andreas Reik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of inactivating a glucocorticoid receptor gene in an isolated cell
    Patent number: 11884930
    Abstract: Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: January 30, 2024
    Assignees: Sangamo Biosciences, Inc., City of Hope
    Inventors: Andreas Reik, Michael Jensen, Michael C. Holmes, Philip D. Gregory, Dale Ando
  • METHODS AND COMPOSITIONS FOR TREATMENT OF A GENETIC CONDITION
    Publication number: 20230416775
    Abstract: Methods and compositions for a genetic disease are provided.
    Type: Application
    Filed: November 7, 2022
    Publication date: December 28, 2023
    Inventors: Gregory J. Cost, Dmitry Guschin, Philip D. Gregory, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • METHODS AND COMPOSITIONS FOR MODULATING PD1
    Publication number: 20220395556
    Abstract: Disclosed herein are methods and compositions for modulating expression of a PD1 gene.
    Type: Application
    Filed: January 28, 2022
    Publication date: December 15, 2022
    Inventors: Philip D. Gregory, Michael C. Holmes, Matthew C. Mendel, Xiangdong Meng, David Paschon, Andreas Reik, Fyodor Urnov
  • Methods and compositions for treatment of a genetic condition
    Patent number: 11492643
    Abstract: Methods and compositions for a genetic disease are provided.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: November 8, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gregory J. Cost, Philip D. Gregory, Dmitry Guschin, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • Methods and compositions for modulating PD1
    Patent number: 11235026
    Abstract: Disclosed herein are methods and compositions for modulating expression of a PD1 gene.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: February 1, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Michael C. Holmes, Matthew C. Mendel, Xiangdong Meng, David Paschon, Andreas Reik, Fyodor Urnov
  • NUCLEASE-MEDIATED REGULATION OF GENE EXPRESSION
    Publication number: 20210348143
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
    Type: Application
    Filed: April 26, 2021
    Publication date: November 11, 2021
    Inventors: Stuart H. Orkin, Andreas Reik, Fyodor Urnov
  • Nuclease-mediated regulation of gene expression
    Patent number: 11021696
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: June 1, 2021
    Assignees: Children's Medical Center Corporation, Sangamo Therapeutics, Inc.
    Inventors: Stuart H. Orkin, Andreas Reik, Fyodor Urnov
  • METHOD OF INACTIVATING A GLUCOCORTICOID RECEPTOR GENE IN AN ISOLATED CELL
    Publication number: 20210102222
    Abstract: Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 8, 2021
    Inventors: Andreas Reik, Michael Jensen, Michael C. Holmes, Philip D. Gregory, Dale Ando
  • METHODS AND COMPOSITIONS FOR MODIFICATION OF A HLA LOCUS
    Publication number: 20210054046
    Abstract: Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.
    Type: Application
    Filed: November 6, 2020
    Publication date: February 25, 2021
    Inventors: Trevor Collingwood, Laurence J.N. Cooper, Philip D. Gregory, Michael C. Holmes, Jeffrey C. Miller, Edward J. Rebar, Andreas Reik, Fyodor Urnov
  • Isolated human cell with an inactivated glucocorticoid receptor gene
    Patent number: 10907175
    Abstract: Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: February 2, 2021
    Assignees: Sangamo Therapeutics, Inc., City of Hope
    Inventors: Andreas Reik, Michael Jensen, Michael C. Holmes, Philip D. Gregory, Dale Ando
  • NUCLEASE-MEDIATED REGULATION OF GENE EXPRESSION
    Publication number: 20210024606
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
    Type: Application
    Filed: September 15, 2020
    Publication date: January 28, 2021
    Inventor: Andreas Reik
  • Methods and compositions for modification of a HLA locus
    Patent number: 10858416
    Abstract: Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: December 8, 2020
    Assignees: Sangamo Therapeutics, Inc., Board of Regents, The University of Texas System
    Inventors: Trevor Collingwood, Laurence J. N. Cooper, Philip D. Gregory, Michael C. Holmes, Jeffrey C. Miller, Edward J. Rebar, Andreas Reik, Fyodor Urnov
  • Nuclease-mediated regulation of gene expression
    Patent number: 10808020
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: October 20, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Andreas Reik
  • METHODS AND COMPOSITIONS FOR INCREASING RNA ACTIVITY IN A CELL
    Publication number: 20200318140
    Abstract: Disclosed herein are methods and compositions for increasing RNA activity in a cell.
    Type: Application
    Filed: April 3, 2020
    Publication date: October 8, 2020
    Inventors: Siyuan Tan, Dale Ando, Andreas Reik, Linhong Li, Madhusudan V. Peshwa, Haiyan Jiang
  • Nuclease-mediated regulation of gene expression
    Patent number: 10619154
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: April 14, 2020
    Assignees: Sangamo Therapeutics, Inc., University of Washington
    Inventors: Andreas Reik, John A. Stamatoyannopoulos, Jeff Vierstra
  • CHIMERIC ANTIGEN RECEPTOR MEDIATED CELL TARGETING
    Publication number: 20190048060
    Abstract: Disclosed herein are methods and compositions for engineering cells to express a CAR where the cells also have inactivated TCR, HPRT, PD1, CISH and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.
    Type: Application
    Filed: August 8, 2018
    Publication date: February 14, 2019
    Inventors: Anthony Conway, Sumiti Jain, Gary K. Lee, Andreas Reik, Lynn N. Truong
  • Methods and compositions for treatment of a genetic condition
    Patent number: 10196652
    Abstract: Methods and compositions comprising a CRISPR/Cas nuclease that cleaves a T cell receptor (TCR) gene and/or human leukocyte (HLA) gene, the nuclease comprising a cleavage domain and a single guide RNA that binds to a target site in the TCR and/or HLA gene.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: February 5, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Gregory J. Cost, Russell Dekelver, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Jianbin Wang, H. Steve Zhang
  • Methods and compositions for treatment of a genetic condition
    Patent number: 10196651
    Abstract: Methods and compositions comprising a CRISPR/Cas nuclease that cleaves a BCL11A gene for the modification of the BCL11A gene and for modification of globin expression.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: February 5, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Gregory J. Cost, Russell Dekelver, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Jianbin Wang, H. Steve Zhang
  • METHODS AND COMPOSITIONS FOR MODULATING PD1
    Publication number: 20180326000
    Abstract: Disclosed herein are methods and compositions for modulating expression of a PD1 gene.
    Type: Application
    Filed: July 12, 2018
    Publication date: November 15, 2018
    Inventors: Philip D. Gregory, Michael C. Holmes, Matthew C. Mendel, Xiangdong Meng, David Paschon, Andreas Reik, Fyodor Urnov
  • METHODS AND COMPOSITIONS FOR MODIFICATION OF A HLA LOCUS
    Publication number: 20180319864
    Abstract: Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.
    Type: Application
    Filed: July 17, 2018
    Publication date: November 8, 2018
    Inventors: Trevor Collingwood, Laurence J.N. Cooper, Philip D. Gregory, Michael C. Holmes, Jeffrey C. Miller, Edward J. Rebar, Andreas Reik, Fyodor Urnov